InDex Pharmaceuticals Holding Investor Relations Material

InDex Pharmaceuticals Holding AB is a Swedish biotechnology company specialising in the development of drugs for inflammatory bowel disease (IBD). The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.